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Inhaled corticosteroids form the mainstay of the treatment and management of asthma and the results of a
meta-analysis comparing two of the most frequently prescribed inhaled corticosteroids, fluticasone propionate and
budesonide, administered in a clinically equivalent 1:2 dose ratio to 1980 patients with asthma, demonstrated that
fluticasone propionate had an improved eYcacy:safety ratio. However, limited data are available on the relative
economic benefits of fluticasone propionate and budesonide. The database for clinically relevant parameters, for
which the eYcacy:safety meta-analysis had demonstrated statistical significance between the two corticosteroids, was
used for this pharmacoeconomic analysis. Treatment with fluticasone propionate was more cost-eVective than
budesonide with respect to improvement in morning peak expiratory flow rate, successfully treated weeks,
symptom-free days, symptom-free 24 h and episode-free days. The costs of treatment for fluticasone propionate and
budesonide were £7.78 per week and £12.33 per week, respectively. The main contributing factor to the higher costs
of budesonide was the higher cost of health care contacts, which were £4.53 per week for budesonide and £0.57 per
week for fluticasone propionate. The pharmacoeconomic diVerence increased in favour of fluticasone propionate as
the criteria for success were made more stringent. These results demonstrate that, for asthma patients requiring
modification of therapy treatment with fluticasone propionate is more eVective and also cheaper, in terms of overall
health-care costs, than treatment with budesonide.
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Asthma is an increasingly common, chronic disease in both
adults and children (1,2) which imposes a substantial
burden on the patient, on the health-care system and
society as a whole in terms of mortality, morbidity and
economic costs (3). In the absence of a cure for the disease,
the goals of asthma care are to avoid mortality, reduce
exacerbations, control symptoms, optimize lung function
and allow patients to lead lives that are as normal as
possible, with cost-eVective management approaches.
Inhaled corticosteroids, which reduce mortality, exacer-
bations and the frequency and severity of symptoms, and
improve patients’ health-related quality of life, form the
mainstay of treatment for all but those with mild intermit-
tent disease. Consequently, national and international
guidelines for the management of asthma recommend the
use of inhaled corticosteroids as first-line therapy in mild
persistent, moderate and severe asthma (4,5).
Of the inhaled corticosteroids currently available, fluti-
casone propionate and budesonide are both commonly0954-6111/99/060402+06 $12.00/0prescribed. Fluticasone propionate possesses the lowest
degree of oral bioavailability and longest pulmonary resi-
dence time, and, once absorbed into the circulation, is
rapidly metabolized (6). Fluticasone propionate is now
recommended for use in asthma at half the dose of other
inhaled steroids (4,7,8). This was confirmed in a recent
meta-analysis involving studies in adults and children
treated with either fluticasone propionate or budesonide
administered at clinically equivalent doses, which demon-
strated that fluticasone propionate is more eVective than
budesonide and at least as safe when given at approxi-
mately half the microgram dose (9).
Although there is clinical evidence to support the
superior eYcacy and safety of fluticasone propionate at
half the microgram dose, there are limited data available
on the relative economic benefits of fluticasone propion-
ate and budesonide. However, evidence of superior
eYcacy and safety should be accompanied by economic
assessments to help health care payers determine
whether additional improvements in health are worth
paying for. Consequently, this article presents the results
of an economic analysis of the fluticasone propionate/
budesonide database that was used for the clinical
meta-analysis and is the first such analysis based on a
large population.? 1999 W. B. SAUNDERS COMPANY LTD
COST-EFFECTIVE TREATMENT OF ASTHMA 403In evaluating the economic benefits of asthma manage-
ment, measures of eVectiveness need to be chosen which
reflect the benefits being paid for. In a comparison between
two treatments, these might reflect the willingness to pay for
improvements in lung function, for better control of symp-
toms and for fewer exacerbations. There is no single, widely
accepted endpoint which captures in an economic sense the
benefits of asthma treatment, though each of the above has
been addressed in separate studies.
Three diVerent approaches have been adopted to address
the multiple objectives of asthma management. Most
studies have focused on a single outcome measure, such as
symptom-free days (10), improvement in lung function (11)
or improvement in health-related quality of life (12).
Second, more than one outcome measure can be reported.
In a study demonstrating the value of inhaled corticoster-
oids, two measures were reported to capture separately the
improvements in lung function and symptom control (13).
Finally, in a study demonstrating the cost-eVectiveness of
salbutamol, a synthetic measure, the ‘episode-free day’, was
devised to measure days free of an adverse event or an
asthma episode, defined as an asthma attack, the need for
rescue medication or sleep disturbance caused by asthma
(14).
The analysis adopted in this study is closest to the
second approach, reporting eVectiveness in meeting the
diVerent goals of asthma management separately. In this
study, it was not possible to explore the impact of treatment
on mortality (there were no deaths recorded in the trials) or
on health-related quality of life (data had not been collected
in any of the studies). However, it was possible to evaluate
the diVerential impact of the two drugs on the other main
goals of asthma management. As such it is one of the first
analyses to characterize cost-eVectiveness using a compre-
hensive range of endpoints, enabling decision-makers to
compare the economic implications of asthma therapy with
fluticasone propionate and budesonide based on a range of
endpoints of importance.Methods
The analysis was conducted from the perspective of the
health-care system. All studies comparing budesonide with
fluticasone propionate at half, or less than half, of the
microgram dose of budesonide, which included daily morn-
ing peak expiratory flow rate (PEFR) as an outcome
measure in patients with asthma, and which were completed
before December 1995, had been included in the clinical
meta-analysis and therefore included in this retrospective
economic analysis. In each of the seven studies identified
(15–21), all patients recorded morning PEFR, severity of
daytime and night-time asthma symptoms, use of rescue
bronchodilator medication and the incidence of exacer-
bations each day on a diary card during the run-in and
treatment periods. Measurements recorded during the week
prior to administration of the first dose of inhaled corticos-
teroid were used to determine mean pre-study values. The
economic evaluation was conducted from a health-care
payer’s perspective.MEASURES OF EFFECTIVENESS
Four measures of eVectiveness were pre-determined for
economic evaluation. For improvements in lung function,
two success criteria were defined: an increase in mean
morning PEFR of §15 l min"1 between pre- and end-of-
treatment; and a successfully treated week, defined as a
week in which there was an improvement in mean morning
PEFR of §5% from baseline (11). For consistency, the
end-of-treatment values used in these lung function-based
measures of eVectiveness were taken as the mean of the
7 days that ended 3 days before the last days of intended
treatment.
For symptom control, the measure was symptom-free
day defined as a 24-h period without any asthma symptoms
being experienced by the patient, as recorded on the
daily diary card. For management of symptoms and
exacerbations, the episode-free day was used (14).COSTS
Total direct health care costs of treatment were calculated
by applying published unit costs to health care resource use
recorded during the studies. Resource use was identified
from data recorded by the patient in the daily diary card
(relief medications), and by the investigator in the concur-
rent medication forms [prescription only treatments for
asthma and those associated with asthma exacerbations or
side-eVects (in eVect, treatments for oral candidiasis)] and
serious adverse event forms (incidence and duration of
hospitalizations). Study medications were costed based on
the dose and frequency specified in the study protocols.
Standard data collection methods were used across the
studies. To account for patient withdrawals and missing
data, two major assumptions were made in the assessment
of resource utilization.
1. Patients who withdrew, or were withdrawn, from a study
were included in the analysis on the assumption that they
were treatment failures. A patient withdrawing early from
the study was assumed to continue using resources at the
same rate as was being used in the time up to withdrawal,
but to incur no further treatment benefits.
2. Information on primary care and emergency room visits
had not been recorded in any of the studies. It was therefore
assumed that a GP visit took place once following an
asthma-related hospitalization and once whenever there
was a change in asthma-related prescription therapy, or on
new prescription of drug treatment for exacerbations or
oral candidiasis. Emergency room visits were assumed to
have occurred if there was evidence of intravenous treat-
ment of severe acute asthma in the absence of a hospital-
ization. Hospitalizations had been recorded; where
duration of hospitalization was not completed, the U.K.
average length of stay for an asthma inpatient episode
was used.
The costs of drugs were obtained from the British
National Formulary in March 1995, and unit costs for
other health-care resources were based on data from the
OYce of Health Economics (22). Mean overall health care
costs (1995 values) were calculated for each treatment arm.
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Mean cost-eVectiveness ratios (cost per symptom-free day,
for example) were calculated and compared across treat-
ment arms for each eVectiveness endpoint. Incremental
cost-eVectiveness ratios (additional cost per additional
symptom-free day, for example) were calculated for each
eVectiveness parameter as the diVerence in the appropriate
average treatment costs between fluticasone propionate and
budesonide divided by the diVerence in success rates. In
order to generate these overall cost-eVectiveness ratios, the
cost-eVectiveness ratios for each study were calculated, and
then pooled by weighting by the number of patients in the
study. The cost per symptom-free day, for example, was
calculated by first deriving individual study results (dividing
the average treatment cost by the average success rate in
each study) and then generating an overall result from the
weighted average of the cost-eVectiveness ratios in the seven
studies.SENSITIVITY ANALYSIS
A potential criticism of economic evaluations is that arbi-
trary thresholds or assumptions may be chosen: to address
this, sensitivity analyses should be performed to explore the
impact of varying the assumptions made. In order to
evaluate the robustness of the data to assumptions used in
this study, sensitivity analyses were conducted on the results
for eVectiveness and for cost.
1. The threshold for success was varied for the eVectiveness
measures based on lung functioning, first with the level of
improvement in mean morning peak flow defining a suc-
cessfully treated week varied between 1 and 10%, and then
with the level of improvement in mean morning peak flow
defining a successfully treated patient varied between 5 and
30 l min"1.
2. In those patients where the length of stay in hospital was
missing, as stated above, the mean U.K. inpatient duration
was used. However, as hospitalization was anticipated to be
a major cost driver in this analysis, the length of stay for
those patients was also varied from 1 to 10 days as part of
the sensitivity analysis.STATISTICAL ANALYSIS
Data from the intention-to-treat populations from all the
studies were used in the statistical analyses. Statistical
diVerences between the two treatment arms were tested for
all eVectiveness measures. The mean proportion of patients
experiencing a 15 l min"1 improvement in PEFR was com-
pared between treatments using a chi-squared test. The
mean proportion of successfully treated weeks, symptom-
free days and episode-free days were compared between the
treatments using a Student’s t-test.Table 1. Studies which provided data for meta-analysis
Study (Ref) Population
Duration
(weeks)
Fluticasone
propionate
(ìg day"1)
Budesonide
(ìg day"1)
1. (20) Adults with severe asthma 12 800 Diskhaler= 1600 Turbuhaler=
2. (21) Steroid-naïve adults with moderate asthma 6 500 MDI 1200 Turbuhaler=
3. (18) Adults with moderate asthma 4 500 Diskus= 1200 Turbuhaler=
4. (15) Adults with moderate asthma 8 400 Diskhaler= 800 Turbuhaler=
5. (19) Paediatric 4 200 Diskus= 400 Turbuhaler=
6. (16) Adults with mild/moderate asthma 8 200 MDI 400 MDI
7. (17) Adults with mild asthma 8 200 Diskhaler= 400 Turbuhaler=
MDI, metered-dose inhaler.Results
The seven studies involved in the meta-analysis on which
this economic analysis is based are summarized in Table 1.
The original clinical meta-analysis demonstrated that fluti-
casone propionate significantly improved mean morning
PEFR compared with budesonide, with a mean diVerence
in improvement of 11 l min"1 (9).
In this economic evaluation, a significantly higher
number of patients receiving fluticasone propionate (49%)
experienced a minimum improvement in mean morning
PEFR of §15 l min"1 compared with 41% of those receiv-
ing budesonide (P<0·001). For the other lung function
measure, the mean proportion of successfully treated weeks
was 41·7% for fluticasone propionate, compared with 34·1%
for budesonide (P<0·001). Assessing asthma symptom con-
trol, the mean percentage of symptom-free days was 41·7%
for fluticasone propionate and 38·2% for budesonide
(P=0·036). For control of symptoms and exacerbations and
the absence of adverse events, the proportion of episode-
free days was 31·0% for fluticasone propionate and 26·7%
for budesonide (P<0·003). In summary, all measures
demonstrated significantly greater benefits with fluticasone
propionate than budesonide.
The total cost per patient is summarized by treatment
arm in Table 2. Overall, mean weekly costs per patient were
£12.33 for budesonide and £7.78 for patients treated with
fluticasone propionate (daily costs were £1.76 and £1.11,
respectively). The main contributing factor to the higher
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higher costs of health care, in particular hospitalization
costs. Overall, the cost of health care contacts was £0.57 per
week for fluticasone propionate compared to £4.53 per
week for budesonide.
Therefore, these results demonstrate that treatment of
asthma patients with fluticasone propionate is both
cheaper, in terms of overall health care costs, and more
eVective. Table 3 summarizes the comparative cost-
eVectiveness of the two corticosteroids for all parameters,
i.e. improvement in mean morning PEFR §15 l min"1,
successfully treated weeks, symptom-free days and episode-
free days. For each of these parameters, fluticasone
propinate was more cost-eVective than budesonide, as
demonstrated by the lower cost-eVectiveness ratios. In
decision making, incremental cost-eVectiveness ratios
(ICERs) are most useful to interpret as they assess the
additional costs required to achieve additional benefits.
However, in this study ICERs were not calculated for any
of the end-points as in all cases the additional benefits0
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Fig. 1. Sensitivity analysis: cost per successfully treated
week (/, fluticasone propionate; ., budesonide).provided by fluticasone propionate were generated at a
lower overall cost, making their calculation redundant.
As part of the sensitivity analysis, the base case for a
successfully treated week of 5% mean improvement in
PEFR over baseline was varied from 1 to 10% PEFR. This
showed that the diVerence in cost-eVectiveness in favour of
fluticasone propionate increased as the level of improve-
ment required to define success increased (Fig. 1). A similar
result was seen when the criterion for improvement in
PEFR over the study period was varied between 5 and
30 l min"1 (Fig. 2).
When the assumed duration of hospitalization was varied
in patients whose length of stay was not recorded, it was
shown that the overall costs of care for the two treatments
remained in favour of fluticasone propionate. Mean daily
costs for fluticasone propionate remained at £1.11 (as there
were no missing hospitalization data in these patients),
whilst costs in the budesonide arm varied from £1.38
(assuming a length of stay of one day where the duration
was missing) to £2.23 assuming the missing lengths of stay
to be 10 days). However, across all variations of the
sensitivity analysis, treatment with fluticasone propionate
remained cheaper overall (and hence more cost-eVective)
than budesonide.Table 2. Weekly treatment costs*
Fluticasone
propionate
(£)
Budesonide
(£)
Study drug 5·70 6·22
Rescue medication 0·20 0·22
Treatment of adverse events 1·35 1·40
Health-care contacts 0·57 4·53
Overall 7·78 12·33
*The cost of drugs was based on the U.K. price listed in the
British National Formulary in March 1995; unit costs for
other health-care resources, e.g. cost of in-patient care,
community health-care contacts, were based on data from
the OYce of Health Economics.
The total values may diVer slightly from the sum of the
individual items because of rounding the values to the
nearest £0·01.Table 3. Summary of comparative mean cost-eVectiveness ratios
Cost eVectiveness endpoint
Mean cost-eVectiveness
Fluticasone
propionate
(£ patient"1)
Budesonide
(£ patient"1)
Cost per improvement in mean morning
PEFR >15 l min"1 over study period
2·55 5·51
Cost per successfully treated week 19·45 41·20
Cost per symptom-free day (24 h period) 2·79 4·64
Cost per episode-free day 4·23 7·31
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The cost-eVectiveness of treatments is now subject to
increasingly detailed scrutiny as the cost of health care
increases and government departments attempt to keep
down costs in an environment where regulatory agencies
are approving drugs at a faster rate than before. The
treatment of asthma therefore, like any other disease, is
becoming the subject of stringent economic evaluation.
Several studies have assessed the costs and cost-
eVectiveness of inhaled steroids in the management of
asthma prior to this study. In clinical practice, an economic
analysis of the addition of inhaled corticosteroids to exist-
ing inhaled bronchodilator treatment showed that while
drug acquisition costs can be up to three times higher in
patients treated with corticosteroids and bronchodilators,
these increases are oVset by a reduction in other health care
costs, such as hospitalization and loss in productivity,
resulting in an overall savings in the use of other health care
resources (23). Similarly, economic evaluation of asthma
therapies in primary care have been reported by Price and
Appleby (24) who demonstrated that, although prescribing
fluticasone propionate to asthma patients in general prac-
tice increased drug acquisition costs, it was accompanied by
a reduction in other health care costs which oVset the
increased prescribing costs.
Asthma is a chronic condition and because the duration
of treatment of the studies used in this economic analysis is
relatively short (4–12 weeks), assessment of long-term eVec-
tiveness and cost-eVectiveness was not possible. In the
absence of evidence to suggest that the diVerences in
eVectiveness would not be sustained, it can be assumed that
the longer the treatment period the greater the benefits and
the cost savings with fluticasone propionate.
This study represents the first large-population economic
evaluation of two frequently prescribed inhaled corticoster-
oids administered under clinical trial conditions at clinically
equivalent doses. Smaller population economic evaluations
involving fluticasone propionate and budesonide have
already been published. Studies involving budesonide inadults and children with asthma have demonstrated that
the increased cost of adding the inhaled corticosteroids to
regular or intermittent bronchodilator administration was
oVset by a reduction in other health-care costs (13,23,25).
Moreover, budesonide at dosages of 400–800 ìg day"1 was
significantly better than placebo when evaluated by how
much a patient was theoretically willing to pay to avoid
asthma and its related complications (26). With respect to
comparative fluticasone propionate–budesonide studies,
one study (27) demonstrated that in steroid-naïve patients,
treatment with fluticasone propionate via a metered-dose
inhaler resulted in lower direct health care cost (DM 4·23
vs. DM 5·19), lower daily costs per successfully treated
patient (DM 9·00 vs. DM 12·36) and lowered the cost per
symptom-free day (DM 10·58 vs. DM 15·26) than budeso-
nide administered at twice the dose via a Turbuhaler=
(Astra Pharmaceuticals). That study formed one of the
seven studies on which this meta-analysis was performed. A
second study (11) demonstrated that although the fluti-
casone propionate-treated group was more expensive than
the budesonide-treated group, fluticasone propionate was
the most cost-eVective treatment once the costs were related
to outcome levels, and the cost-eVectiveness gap widened in
favour of fluticasone propionate as the minimum improve-
ment in PEFR used in the definition of success was
increased. A third study (28) came to the conclusion that
budesonide was more cost-eVective than fluticasone propi-
onate. However this evaluation did not use clinically
equivalent doses as it used the two drugs at a 1:1 dose ratio
whereas, as stated in the British Thoracic Society Guide-
lines, fluticasone propionate can be considered to be twice
as potent as budesonide (4).
Using published economic results for decision-making in
a local setting requires not only assessments of the quality
and relevance of the evidence, but also estimates of the
costs and eVectiveness likely to be seen locally rather than
in the clinical trial setting, and a judgement over the relative
importance or value of the improvements in eVectiveness.
Although there is debate over the choice of endpoints for
measuring eVectiveness in economic analyses in asthma, the
endpoints used in this study have been used in other
published studies and cover most of the goals of asthma
management. In interpreting these multiple endpoints for
choice of asthma therapy in a local setting, the decision-
maker needs to evaluate to what extent the range of
improvements in the diVerent outcomes are worth while
overall. With the cost savings shown in this study, the
results suggest that this will be straightforward: improve-
ments in asthma management can be achieved in parallel
with reductions in cost.
Thus, in addition to fluticasone propionate having a
greater eYcacy:safety ratio than budesonide in both
paediatric and adult asthma (9), fluticasone propionate
was also most cost-eVective than budesonide in these
patients.0
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Fig. 2. Sensitivity analysis: cost per improvement in
morning peak expiratory flow rate (PEFR) (/, fluticasone
propionate; ., budesonide).References
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